Besides, WP1066, a STAT3 inhibitor, exhibited anti-cancer effects in multiple tumors [42, 43], including lymphoma [24], and we found WP1066 enhanced the inhibitory effects of AT56 on DLBCL progression. This evidence concerns the gene STAT3 and cancer.